AP2174A - Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation. - Google Patents

Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.

Info

Publication number
AP2174A
AP2174A AP2006003580A AP2006003580A AP2174A AP 2174 A AP2174 A AP 2174A AP 2006003580 A AP2006003580 A AP 2006003580A AP 2006003580 A AP2006003580 A AP 2006003580A AP 2174 A AP2174 A AP 2174A
Authority
AP
ARIPO
Prior art keywords
inflamation
hiv
treatment
receptor antagonist
antagonist activity
Prior art date
Application number
AP2006003580A
Other languages
English (en)
Other versions
AP2006003580A0 (en
Inventor
Paul Anthony Stupple
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0323236.0A external-priority patent/GB0323236D0/en
Priority claimed from GB0325020A external-priority patent/GB0325020D0/en
Priority claimed from GB0418566A external-priority patent/GB0418566D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AP2006003580A0 publication Critical patent/AP2006003580A0/xx
Application granted granted Critical
Publication of AP2174A publication Critical patent/AP2174A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
AP2006003580A 2003-10-03 2004-09-28 Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation. AP2174A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0323236.0A GB0323236D0 (en) 2003-10-03 2003-10-03 Chemical compounds
GB0325020A GB0325020D0 (en) 2003-10-27 2003-10-27 Chemical compounds
GB0418566A GB0418566D0 (en) 2004-08-19 2004-08-19 Tropane derivatives
PCT/IB2004/003153 WO2005033107A1 (en) 2003-10-03 2004-09-28 Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation

Publications (2)

Publication Number Publication Date
AP2006003580A0 AP2006003580A0 (en) 2006-04-30
AP2174A true AP2174A (en) 2010-11-20

Family

ID=34426592

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003580A AP2174A (en) 2003-10-03 2004-09-28 Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.

Country Status (35)

Country Link
US (2) US7309790B2 (ja)
EP (1) EP1682545B1 (ja)
JP (1) JP4874107B2 (ja)
KR (1) KR100777885B1 (ja)
AP (1) AP2174A (ja)
AR (1) AR045856A1 (ja)
AT (1) ATE380813T1 (ja)
AU (1) AU2004278158B2 (ja)
BR (1) BRPI0414862A (ja)
CA (1) CA2540834C (ja)
CY (1) CY1107281T1 (ja)
DE (1) DE602004010708T2 (ja)
DK (1) DK1682545T3 (ja)
EA (1) EA009941B1 (ja)
EC (1) ECSP066475A (ja)
ES (1) ES2295924T3 (ja)
GE (1) GEP20084417B (ja)
HN (1) HN2004000383A (ja)
HR (1) HRP20080052T3 (ja)
IL (1) IL174208A0 (ja)
MA (1) MA28080A1 (ja)
MX (1) MXPA06003749A (ja)
MY (1) MY137609A (ja)
NO (1) NO20061978L (ja)
NZ (1) NZ545837A (ja)
OA (1) OA13266A (ja)
PA (1) PA8614301A1 (ja)
PE (1) PE20050961A1 (ja)
PL (1) PL1682545T3 (ja)
PT (1) PT1682545E (ja)
RS (1) RS20060198A (ja)
SI (1) SI1682545T1 (ja)
TW (1) TWI280244B (ja)
UY (1) UY28546A1 (ja)
WO (1) WO2005033107A1 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
WO2007114921A2 (en) * 2006-04-05 2007-10-11 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one and treatment methods using the same
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
DE602007012363D1 (de) 2006-10-19 2011-03-17 Rigel Pharmaceuticals Inc 2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen
US20090325936A1 (en) * 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
MX2010004493A (es) * 2007-10-25 2010-06-11 Exelixis Inc Compuestos de tropano.
LT2265607T (lt) 2008-02-15 2017-03-27 Rigel Pharmaceuticals, Inc. Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
SG10201407538WA (en) 2009-08-14 2015-01-29 Opko Health Inc Intravenous formulations of neurokinin-1 antagonists
EA201290852A1 (ru) 2010-04-02 2013-04-30 ФИВКО-1 ЭлЭлСи Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
PL3049378T3 (pl) * 2013-09-25 2019-06-28 SpecGx LLC Wytwarzanie radiojodowanego 3-fluoropropylo-nor-beta-CIT
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2023192360A1 (en) * 2022-03-31 2023-10-05 Incelldx, Inc. Methods of treating a subject for post-treatment lyme disease (ptld) and compositions for use in the same
WO2023192361A1 (en) * 2022-03-31 2023-10-05 Incelldx, Inc. Methods of treating a subject for fibromyalgia and compositions for use in the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038680A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Azabicycloalkanes as ccr5 modulators
WO2001090106A2 (en) * 2000-05-26 2001-11-29 Pfizer Limited Tryasolyl tropane derivatives as ccr5 modulators
WO2003084954A1 (en) * 2002-04-08 2003-10-16 Pfizer Limited Tropane derivatives as ccr5 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DK0756596T3 (da) 1994-04-19 2002-12-23 Neurosearch As Tropan-2-aldoximderivater som neurotransmitter-genoptagelsesinhibitorer
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
PT885220E (pt) 1996-02-22 2001-11-30 Neurosearch As Derivados de tropano a sua preparacao e utilizacao
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6855724B2 (en) * 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038680A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited Azabicycloalkanes as ccr5 modulators
WO2001090106A2 (en) * 2000-05-26 2001-11-29 Pfizer Limited Tryasolyl tropane derivatives as ccr5 modulators
WO2003084954A1 (en) * 2002-04-08 2003-10-16 Pfizer Limited Tropane derivatives as ccr5 modulators

Also Published As

Publication number Publication date
UY28546A1 (es) 2005-05-31
MA28080A1 (fr) 2006-08-01
IL174208A0 (en) 2006-08-01
DE602004010708D1 (de) 2008-01-24
EA009941B1 (ru) 2008-04-28
US7790740B2 (en) 2010-09-07
US20050131011A1 (en) 2005-06-16
MXPA06003749A (es) 2006-06-14
SI1682545T1 (sl) 2008-04-30
EP1682545B1 (en) 2007-12-12
BRPI0414862A (pt) 2006-11-28
AP2006003580A0 (en) 2006-04-30
JP4874107B2 (ja) 2012-02-15
AR045856A1 (es) 2005-11-16
NO20061978L (no) 2006-07-03
CY1107281T1 (el) 2012-11-21
ECSP066475A (es) 2006-10-10
ATE380813T1 (de) 2007-12-15
DE602004010708T2 (de) 2008-12-04
WO2005033107A1 (en) 2005-04-14
US20080045563A1 (en) 2008-02-21
TW200519112A (en) 2005-06-16
PL1682545T3 (pl) 2008-04-30
TWI280244B (en) 2007-05-01
JP2007507483A (ja) 2007-03-29
EP1682545A1 (en) 2006-07-26
US7309790B2 (en) 2007-12-18
PA8614301A1 (es) 2005-05-10
PE20050961A1 (es) 2005-11-29
MY137609A (en) 2009-02-27
EA200600480A1 (ru) 2006-08-25
HN2004000383A (es) 2008-10-14
CA2540834A1 (en) 2005-04-14
HRP20080052T3 (en) 2008-02-29
DK1682545T3 (da) 2008-03-17
NZ545837A (en) 2009-12-24
CA2540834C (en) 2010-06-22
AU2004278158B2 (en) 2009-08-13
KR20060070571A (ko) 2006-06-23
GEP20084417B (en) 2008-07-10
PT1682545E (pt) 2008-02-11
OA13266A (en) 2007-01-31
KR100777885B1 (ko) 2007-11-28
RS20060198A (en) 2008-09-29
ES2295924T3 (es) 2008-04-16
AU2004278158A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
AP2174A (en) Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.
ZA200702772B (en) Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists
IL160974A0 (en) Piperazine derivatives with ccr1 receptor antagonist activity
NO20020392D0 (no) Nociceptinreseptor ORL-1-agonister for anvendelse ved behandling av hoste
HK1076102A1 (en) Tropane derivatives as ccr5 modulators
IL178334A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
DE60021370D1 (de) Piperazinderivate verwendbar als ccr5 antagonisten
IL174952A0 (en) Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
IL160896A0 (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
ZA200108867B (en) Piperidine derivatives useful as CCR5 antagonists.
HUP0600858A2 (en) Piperizinyilpiperidine derivatives as chemokine receptor antagonists
MY139720A (en) Micronized crystalline tiotropium bromide
PL369758A1 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
IL183485A0 (en) Therapeutic pyrazolo[3,4-b] pyridines and indazoles
AU2003267088A8 (en) Chemokine receptor antagonists as therapeutic agents
PL370910A1 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
HK1126200A1 (en) Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
AP2005003196A0 (en) Bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor.
PL372701A1 (en) Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane as nmda, 5ht3, and neuronal nicotinic receptor antagonists
PL1644012T3 (pl) Czwartorzędowe pochodne chelidoniny i alkaloidów, sposób ich otrzymywania oraz zastosowanie do wytwarzania środków leczniczych
WO2003080118A3 (en) Combination of an aldosterone receptor antagonist and a fibric acid derivative
SI1305047T1 (sl) Nepeptidni CCR1 receptorski antagonisti v kombinaciji s ciklosporinom A za zdravljenje zavrnitve srcnega transplantata